JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

JNJ

233.9

+0.21%↑

UNH

278.18

-1.9%↓

TMO

572.77

-1.84%↓

ABT

108.41

+0.25%↑

ISRG

475.79

-3%↓

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Avatud

35.8 -5.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.63

Max

37.61

Põhinäitajad
By Trading Economics
Sissetulek	-7.4M -81M
Aktsiakasum	-0.5
Töötajad	205
EBITDA	-6.8M -79M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+40.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	3.6B 5.8B
Eelmine avamishind	41.54
Eelmine sulgemishind	35.8

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. veebr 2026, 23:11 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. veebr 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. veebr 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. veebr 2026, 23:38 UTC

Tulu

AMD Sales Climb on Help From Data-Center Business -- Update

3. veebr 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. veebr 2026, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. veebr 2026, 23:25 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. veebr 2026, 23:23 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. veebr 2026, 23:22 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. veebr 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. veebr 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. veebr 2026, 22:56 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. veebr 2026, 22:40 UTC

Tulu

Amdocs Extends Collaboration With T-Mobile

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Adj EPS $1.81

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Rev $1.16B

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q EPS $1.45 >

3. veebr 2026, 22:38 UTC

Tulu

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. veebr 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. veebr 2026, 22:14 UTC

Tulu

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. veebr 2026, 22:13 UTC

Tulu

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. veebr 2026, 22:12 UTC

Tulu

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. veebr 2026, 22:10 UTC

Tulu

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. veebr 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

40.16% tõus

12 kuu keskmine prognoos

Keskmine 50.33 USD 40.16%

Kõrge 67 USD

Madal 34 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.